1. Bosch, FX, et al. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55: 244–265.
2. Dasbash, EJ, Elbasha, H, Insinua, RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiologic Reviews 2006; 28: 88–100.
3. Elbasha, EH, Dasbach, EJ, Insigna, RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease 2007; 13: 28–41.
4. Beck, JR, Pauker, SG. The Markov process in medical prognosis. Medical Decision Making 1983; 3: 419–458.
5. Elbasha, EH, Galvani, AP. Vaccination against multiple HPV types. Mathematical Biosciences 2005; 197: 88–117.
6. Plummer, M, et al. A 2-years prospective study of HPV persistence among women with Ascus or LSIL cytology. Journal of Infectious Diseases 2007; 195: 1582–1589.
7. ISTAT 14th Italian population census. 21 October 2001 (www.demoistat.it). Accessed 8 January 2008.
8. Winer, RL, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 2008; 197: 279–282.
9. Winer, RL, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology 2003; 157: 218–226.
10. Brown, DR, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. Journal of Infectious Diseases 2005; 191: 182–192.
11. Sharma, R, Sharma, CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. Journal of Cancer Research and Therapeutics 2007; 3: 92–95.
12. Garnett, GP, et al. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 (Suppl. 3): 178–86.
13. Munoz, N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527.
14. Pagliusi, SR, et al. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569–578.
15. Mao, C, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstretics and Gynecology 2006; 107: 18–27.
16. Paavonen, J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–2170.
17. Joura, EA, et al. Efficacy of a quadrivalent prophylactic human against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–1702.
18. Harper, DM, et al. Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human Papillomavirus types 16 and 18: follow-up from a randomised trial. Lancet 2006; 367: 1247–1255.
19. Villa, LL, et al. High sustained efficacy of a prophylactic quadrivalent human Papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 2006; 95: 1459–1466.
20. Sewell, EC, Jacobson, SH, Weniger, BG. ‘Reverse engineering’ a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Pediatric Infectious Disease Journal 2001; 20 (Suppl. 11): S45–S56.
21. Coudeville, L, et al. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22: 839–855.
22. Bosch, FX, de, Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers 2007; 23: 213–227.
23. Woodman, CB, Collins, SI, Young, LS. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 2007; 7: 11–22.
24. Barnabas, RV, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling Analysis. PLOS Medicine 2006; 3: 624–632.
25. Markowitz, LE, et al. Quadrivalent human papillomavirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2007; 56: 1–24.
26. Saslow, D, et al. American Cancer Society Guideline for human Papillomavirus (HPV). Vaccine use to prevent cervical cancer and its precursors. A Cancer Journal for Clinicians 2007; 57: 7–28.
27. Garland, SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928–1943.